OptiScan Biomedical

Primary contact

OptiScan Biomedical has developed innovative continuous monitoring systems for use in hospital intensive care units (ICUs). The company's OptiScanner 5000 is a first-of-its-kind automated, bedside glucose monitoring system that provides accurate, automated monitoring of patients' glucose levels measured in plasma, as opposed to whole blood. The system prominently displays glucose level trend data updated every 15 minutes to help manage patients' glucose levels within an optimum target range. Also if needed, the OptiScanner 5000 will alert clinicians to the existence of hyperglycemia (values that are too high) and hypoglycemia (values that are too low). OptiScan Biomedical is also expanding the capabilities of the OptiScanner platform (OptiScanner 6000) to detect additional metabolic and hemodynamic analytes within the same blood sample, which will provide valuable trending data about the condition of a critically ill patient. The company has received CE Mark certification for the OptiScanner 5000/6000 system; it has also completed a pivotal, multi-center Investigational Device Exemption (IDE) clinical study.
Primary contact

Funding 💰

Total $130.2M
Select investors NGN Capital, MedVenture Associates, Morgenthaler Ventures, Wexford Capital, JJDC, Oakwood Medical Investors, CCMP Capital, Mitsui Global Investment, Prism Venture Management
Last update: April 13, 2018